PriceTargets.com logo

Atossa Therapeutics - ATOS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 573.08%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.04 As of 12/17/2024 01:00 AM ET
▼ -0.03 (-2.80%)

This chart shows the closing price for ATOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Atossa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATOS

Analyst Price Target is $7.00
▲ +573.08% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Atossa Therapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 573.08% upside from the last price of $1.04.

This chart shows the closing price for ATOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Atossa Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
12/9/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.50 ➝ $7.00
11/13/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $7.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
9/11/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.25 ➝ $6.50
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
6/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
6/20/2024Cantor FitzgeraldReiterated RatingOverweight
6/6/2024Ascendiant Capital MarketsBoost TargetBuy ➝ Buy$6.00 ➝ $6.25
5/14/2024Cantor FitzgeraldReiterated RatingOverweight
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $6.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00
4/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$4.00
2/12/2024HC WainwrightReiterated RatingBuy$4.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
12/18/2023Cantor FitzgeraldReiterated RatingOverweight
9/8/2023Cantor FitzgeraldInitiated CoverageOverweight$5.00
11/16/2022Ascendiant Capital MarketsLower Target$6.00
8/22/2022Ascendiant Capital MarketsLower Target$7.00
9/18/2020Maxim GroupReiterated RatingBuy$8.00
9/17/2020Ascendiant Capital MarketsInitiated CoverageBuy$7.00
7/31/2020Maxim GroupReiterated RatingBuy$8.00
7/17/2020Maxim GroupBoost Target$4.00 ➝ $8.00
7/16/2020Maxim GroupReiterated RatingPositive
5/23/2020Maxim GroupInitiated CoverageBuy$4.00
4/28/2020Maxim GroupInitiated CoverageBuy$4.00
4/17/2020Maxim GroupReiterated RatingBuy$4.00
12/18/2019Maxim GroupUpgradeHold ➝ Buy
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/18/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2024

Current Sentiment

  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Atossa Therapeutics logo
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $1.04
Low: $1.00
High: $1.08

50 Day Range

MA: $1.35
Low: $1.07
High: $1.62

52 Week Range

Now: $1.04
Low: $0.70
High: $2.31

Volume

1,702,934 shs

Average Volume

1,064,028 shs

Market Capitalization

$130.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Atossa Therapeutics?

The following Wall Street research analysts have issued stock ratings on Atossa Therapeutics in the last year: Ascendiant Capital Markets, Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for ATOS.

What is the current price target for Atossa Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Atossa Therapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 573.1%. Ascendiant Capital Markets has the highest price target set, predicting ATOS will reach $7.00 in the next twelve months. Ascendiant Capital Markets has the lowest price target set, forecasting a price of $7.00 for Atossa Therapeutics in the next year.
View the latest price targets for ATOS.

What is the current consensus analyst rating for Atossa Therapeutics?

Atossa Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATOS will outperform the market and that investors should add to their positions of Atossa Therapeutics.
View the latest ratings for ATOS.

What other companies compete with Atossa Therapeutics?

Other companies that are similar to Atossa Therapeutics include PureTech Health, Humacyte, AnaptysBio, CorMedix and Mereo BioPharma Group. Learn More about companies similar to Atossa Therapeutics.

How do I contact Atossa Therapeutics' investor relations team?

Atossa Therapeutics' physical mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company's listed phone number is (206) 588-0256 and its investor relations email address is [email protected]. The official website for Atossa Therapeutics is atossatherapeutics.com. Learn More about contacing Atossa Therapeutics investor relations.